BACKGROUND: With the advent of @entity4149 kinase inhibitors (TKIs), the prognosis of @entity1860 ( @entity1860 ) has undergone significant changes in all age groups and at different clinical stages over the past 15 years. Consequently, although disease incidence has remained stable, cumulative prevalence is increasing. @entity1 AND METHODS: We reviewed our experience with @entity2213 (IM) as a first- and second-line treatment for different @entity1860 to examine demographic and clinical characteristics of @entity1 , cytogenetic and molecular response rates, as well as @entity1349 ( @entity1349 ), progression-free survival, and event-free survival of @entity1 at the Specialties Hospital of the National Medical Center "La Raza," which belongs to the Mexican Social Security Institute and serves a population with medium to low socioeconomic status. RESULTS: We analyzed data of 302 @entity1860 @entity1 who received IM as a first- (n = 234) or second-line treatment (n  = 68). Overall, 198 of 302 @entity1 (66%) reached a complete cytogenetic response and at least 115 of 302 (38%) achieved a major molecular response. Among 302 IM-treated @entity1 , 55 (18%) achieved a molecular response 4.5 (MR4.5) or major; at the time of writing this report, 283 (93.7%) were alive and 19 (6.29%) had died. At 60 months, @entity1349 was 94%. CONCLUSION: IM offers long-term @entity1349 expectations not previously observed with any other therapy, in addition to a good quality of life. However, more than a third of the @entity1 require further treatment with a second-generation TKI; consequently, expectations for treatment-free remission and long-term @entity1349 are reduced. Timely change to second-generation TKIs could improve such expectations.

Diagnosis and Treatment of XXXX in the @entity2213 Era: Report of the Experience at "La Raza" Medical Center in Mexico.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia', 'CML stages'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib mesylate']
@entity1860 :: (MESH:D015464,Disease) :: ['Chronic Myeloid Leukemia']
